Torthaí cuardaigh - Matko Kalac

  • 1 - 5 toradh as 5 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

    Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma de réir Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Ellen Neylon, Paul Johannet, Ying Wei, Jasmine Zain, Owen A. O’Connor

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

    Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma de réir Matko Kalac, Salvia Jain, Constantine S. Tam, Zhengrui Xiao, Francesca Montanari, Jennifer A. Kanakry, Bryan D. Huber, Mendel Goldfinger, Owen A. O’Connor, Enrica Marchi

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

    HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL de réir Matko Kalac, Luigi Scotto, Enrica Marchi, Jennifer E. Amengual, Venkatraman Seshan, Govind Bhagat, Netha Ulahannan, Violetta V. Leshchenko, Alexis M. Temkin, Samir Parekh, Benjamin Tycko, Owen A. O’Connor

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

    A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma de réir Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine E. Atkins, Aishling M. Rada, Hye A. Kim, Codruța Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, Mark A. Francescone, Lawrence Schwartz, Serge Cremers, Owen A. O’Connor

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

    Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial de réir Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas, Jennifer E. Amengual, Changchun Deng, Matko Kalac, Lorenzo Falchi, Enrica Marchi, Ithamar Turenne, Renee Lichtenstein, Celeste Rojas, Mark Francescone, Lawrence H. Schwartz, Bin Cheng, Kerry J. Savage, Diego Villa, Michael Crump, Anca Prica, Vishal Kukreti, Serge Cremers, Joseph M. Connors, John Kuruvilla

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: